Search
Trazodone
go.drugbank.com/drugs/DB00656ApprovedInvestigational[T646] It was initially granted FDA approval in 1981.[L3484] … [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine
Products: TRAMADOL GOTAS 100 MG/ML, TRAMADOL GOTASX100 MG/MLNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. … [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigationalCFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.
Almasilate
go.drugbank.com/drugs/DB13595ApprovedAlmasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].
Sorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalSorafenib is a bi-aryl urea and an oral multikinase inhibitor. … It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis.
Methyltestosterone
go.drugbank.com/drugs/DB06710ApprovedInvestigationalAlso, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.
Synonyms: 17α-methyl-Δ4-androsten-17β-ol-3-one, 17alpha-Methyl-3-oxo-4-androsten-17beta-olGlasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalCurrently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due … [A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined
mRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalTaurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine]. … It was first synthesized in the 1970s and was originally used as a prophylactic against intraperitoneal bacterial infections in patients with peritonitis.
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawnFlecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.
Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class IcProducts: FLECAINIDACETAT AL 50MG, FLECAINIDACETAT AL 100MG